Expert Interview
Discussing Novo Nordisk's Phase 3 HIBISCUS Trial on Etavopivat (Erythrocyte Pyruvate Kinase Activator) for Sickle Cell Disease
Ticker(s): NVO, NVS, PFE, VRTX, BLUEInstitution: Emory School of Medicine
- Pediatric and Adult Hematologist specializing in transfusion medicine and sickle cell disease; Associate Professor of Pathology and Pediatrics at Emory School of Medicine; Assistant Director of Transfusion Services at Children’s Healthcare of Atlanta
- Manages 300 pediatric and 300 adult patients with sickle cell disease
- Specializes in sickle cell disease and tranfusion medicine for both pediatric and adult patients; leads research in this population at Grady's Comprehensive Sickle Cell Center; PI and Co-I for dozens of SCD studies (industry-funded and NIH)
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
